Bluegrass Vascular Technologies has announced that, effective 1 January 2023, it will assume full responsibility for the sales and distribution of the Surfacer inside-out access catheter system.
As the developer and manufacturer of the Surfacer system, as well as the company that successfully implemented all of the regulatory, clinical research and reimbursement initiatives associated with the device, Bluegrass is “well qualified” to take on this responsibility, according to a recent update shared via LinkedIn.
“We have put in place a sales team with extensive experience selling and supporting vascular interventional products and procedures, and have also engaged several experienced Surfacer system proctors to provide our customers first-in-class clinical support,” the update notes.
The Surfacer system employs a novel inside-out approach to facilitate upper body central venous access in patients with venous obstructions or other conditions that preclude access by conventional methods. By avoiding left-side catheter placement, the US Food and Drug Administration (FDA)-approved and CE-marked device is intended to allow for the placement and maturation of permanent arteriovenous access options that are associated with improved patient outcomes, and a reduced cost of care, for both hospitals and haemodialysis providers.
Earlier this year, Bluegrass also announced it had closed US$5 million in new convertible debt financing.
